For individuals living with treatment-resistant depression, traditional medications may not always provide the relief they need. Two innovative treatment options that have gained attention are Spravato and IV Ketamine. While both are related, they differ in important ways.
Spravato is an FDA-approved prescription nasal spray that contains esketamine, a form of ketamine. It is specifically approved for adults with treatment-resistant depression and certain cases of major depressive disorder. Spravato is administered in a certified healthcare setting under medical supervision.
IV Ketamine involves delivering ketamine directly into the bloodstream through an intravenous infusion. While ketamine has long been used as an anesthetic, its use for depression is considered an off-label treatment. Many patients seek IV Ketamine when other treatments have not been effective.
The biggest difference is FDA approval. Spravato has been extensively studied and approved specifically for depression treatment, while IV Ketamine is used off-label.
Administration also differs. Spravato is delivered through a nasal spray, while IV Ketamine requires an infusion. Both treatments require monitoring by healthcare professionals due to potential side effects such as dizziness, increased blood pressure, or temporary dissociation.
The best choice depends on your diagnosis, treatment history, medical needs, and provider recommendations. What works well for one person may not be the best fit for another.
At Pinnacle Behavioral Healthcare, we understand that depression treatment is not one-size-fits-all. Our team works closely with patients to evaluate available options and develop personalized treatment plans that support long-term mental wellness.
If you are exploring advanced treatments for depression, contact Pinnacle Behavioral Healthcare today to schedule a consultation and learn which option may be right for you.
